Immunogenicity Studies for Biotherapeutics
As we enter our 7th year for Immunogenicity Studies for Biotherapeutics
conference, our faculty remains committed to bringing you the latest new
data and clarification on emerging regulatory guidances for assay
development and validation in immunogenicity studies.
This conference provides you leading-edge information on new
technologies to identify, characterize and reduce antibody and cell-based
responses during discovery, development, pre-clinical and clinical
studies. Case studies with new data on selection, development and
validation of screening, neutralizing, and confirmatory assays in
processes and techniques improvement strategies are featured over all
three days of the conference.
As IIR specializes in the development of Immunogenicity conferences,
we recognize the evolving challenges faced by scientists working on
immunogenicity studies and make it our top priority to be first at
providing new immunogenicity study data and solutions.
For registration information, early registration prices and group discounts
please see page seven. We look forward to welcoming you to the
conference in San Francisco.
Sincerely,
Anne Reel, Program Director, IIR Valerie Bowling, General Manager, IIR
